Washington, Aug 4 (ANI): The new anti-wrinkle facial filler Dysport, which could be used as an alternative to Botox, can also help reduce frown lines between the eyes, reveals a new study.
The study led by plastic surgeons at UT Southwestern Medical Centre has shown that 87 percent of people given Dysport reported a reduction in wrinkles, compared with 5 percent of patients taking placebos.
The Food and Drug Administration-approved study involved 816 participants with moderate to severe frown lines (called glabellar lines).
The study participants, who kept diaries for the first 14 days after being injected, were given the Dysport facial filler or a placebo.
Surgeons injected Dysport in various levels, dependent on sex and facial mass, at five facial points.
Self-assessments and assessments by independent reviewers were performed six times over a five-month follow-up period.
Eighty-seven percent of people given Dysport reported a reduction in wrinkles, compared with 5 percent of patients taking placebos who reported an improvement.
An independent assessment showed improvement among 85 percent of patients receiving Dysport, compared with 3 percent of patients receiving the placebo.
The study is available online and will appear in Plastic and Reconstructive Surgery.
It was found that Dysport took effect as quickly as 24 hours, with the median time about four days.
The study also confirmed that dosing should be adjusted according to a person's facial muscle mass.
Participants with the smallest muscle mass had the largest response (96 percent) by 30 days. That rate dropped as low as 80 percent in people with the highest facial muscle masses.
"Our study confirmed that Dysport (abobotulinumtoxinA) is a safe and effective tool in fighting wrinkles," said Dr. Rod Rohrich, chairman of plastic surgery at UT Southwestern and one of the study's authors.
"It also confirmed that the dosage should be tailored to one's facial muscle mass to be most effective. So it's important to visit with a certified plastic surgeon to ensure the dosage is correct," he added.
The study is available online and will appear in Plastic and Reconstructive Surgery. (ANI)